Juniper Pharmaceuticals (Nasdaq: JNP) a women's health therapeutics company, today announced that it has been recognized as one of greater Boston's 15 companies with the most diverse boards, the GK15. The Company accepted the award at the Get Konnected! 9th Anniversary professional networking event on Tuesday, March 28 in Boston.

"Not only is our Board of Directors accomplished and highly qualified in providing strategic guidance as we build a pipeline of women's health therapeutics, the diversity of membership seen on our Board is reflective of the real world," said Alicia Secor, Juniper's Chief Executive Officer.

"Diversity is of crucial importance to our corporate culture, and evidence supports that having a balanced and diverse Board is associated with increased innovation, competitiveness and sustainable growth, not to mention a more prosperous and inclusive workplace."

In addition to honoring members of the GK15, the event included a panel discussion and a fireside chat on gender and racially diverse corporate boards.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the 505(b)(2) regulatory pathway. Targeted product development investments are enabled by Juniper's core operating business: the Crinone®(progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. Please visit www.juniperpharma.com for more information.